BioIntelliSense health monitoring service raises $ 45 million
- Continuous health monitoring company BioIntelliSense raises $ 45 million. These are the details.
BioIntelliSense – a continuous health monitoring and clinical intelligence company – recently announced the closing of a significantly oversubscribed Series B funding round of $ 45 million. This funding round followed previous Series A funding completed in 2019 and a Series A-Prime completed in 2020 to support BioIntelliSense’s continued growth and global expansion of its medical grade wearable devices and healthcare services. advanced data for scalable remote care.
The Series B funding participation was led by Chimera (UAE) and joined by 7wire Technology Partners, Mary Tolan of Chicago Pacific Founders, James Murren, formerly of MGM Resorts International, as well as Pendrell Corporation, Royal Philips and Fresenius Medical Care . North America. And these parties joined existing Series A funding investors, namely TripleTree Holdings, UCHealth and the CU Healthcare Innovation Fund.
BioIntelliSense opens a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). And its medical-grade Data-as-a-Service (DaaS) platform captures multi-parameter vital signs, physiological biometrics, and symptomatic events through an effortless patient experience.
FDA approved medical grade BioSticker and BioButton devices simplify remote monitoring and early detection. And thanks to the platform’s advanced analytics, clinicians will now have access to high-resolution patient trends and reports to enable medical-grade home care.
“This series of strategic investments further validates our accomplishments to date and marks an important step in the growth and expansion of BioIntelliSense. We proudly launched our Data-as-a-Service clinical intelligence platform, along with our FDA-approved flagship BioSticker ™ medical device, in January 2020. This first multiparameter wearable device and data services for continuous monitoring vital signs, paved the way for the rapid acceleration and commercial launch of the BioButton® health screening solution to address the COVID-19 pandemic and remote care. This model of success is a testament to our collective passion and unwavering commitment to serving patients, the healthcare community, and our valued strategic partners and investors. With this strong financial support, the BioIntelliSense team will continue to innovate and commercialize its growing portfolio of wearable devices and medical-grade data services in all healthcare settings, while having a profound impact on the delivery of personalized care. , worldwide. “
– James Mault, MD, CEO of BioIntelliSense
“The burden of the COVID-19 pandemic and the increasing prevalence of chronic disease has resulted in an exponential global demand for remote care technologies that provide better patient care at a fraction of the cost. BioIntelliSense is uniquely positioned to respond to the initiatives of healthcare providers and population health with its proprietary portfolio of biosensors and data science that combines unparalleled user experience with medical grade clinical precision for remote care profitable and scalable. As the BioIntelliSense Series B Fundraiser, we are excited to support the company’s innovation, global reach and adoption.
– Syed Basar Shueb, chairman of Chimera (UAE), member of the royal group of Abu Dhabi
“The remote patient monitoring market is in hyper-growth mode with projections reaching $ 117.1 billion by 2025. BioIntelliSense is set to expand its footprint with provider and payer organizations looking to accelerate and operationalize their virtual care programs by deploying effortless medical-grade monitoring and follow-up. advanced analytics designed to be scalable.
– Lee Shapiro, former CFO of Livongo Health and co-founder and managing partner of 7wireVentures
“BioIntelliSense represents the future of healthcare; medical-grade surveillance with the best data science powering life-changing AI and prescriptive analytics at a reasonable cost. As one of BioIntelliSense’s first partners, UCHealth is already using this technology to remotely observe patients for deterioration, allowing early intervention to improve outcomes.
– Dr. Richard Zane, Director of Innovation at UCHealth and Professor and Chair of Emergency Medicine at the University of Colorado School of Medicine
“The digital transformation within the retirement home and post-acute care market that optimizes clinical workflow, care pathways and reimbursement models is proven to benefit the provider-patient experience. BioIntelliSense represents a new standard for remote patient monitoring that aligns with CMS reimbursement codes and bulk payments to support a continuous care model based on sophisticated wearable biosensor technology and actionable clinical intelligence.
– Mary Tolan, private investor, co-founder and CEO of Chicago Pacific Founders
“In today’s business environment, data is a currency. BioIntelliSense leverages passive continuous health monitoring data and applies advanced algorithmic analyzes to deliver a personalized care experience for better clinical and financial outcomes. Its Data-as-a-Service (DaaS) platform leverages the latest sensor and wireless technologies, while adhering to strict privacy and security standards, allowing healthcare organizations to evolve with confidence.
– Craig McCaw, President and Co-CEO of Pendrell Corporation
“Philips Ventures is leveraging its targeted investments and collaborations to help develop solutions that enable healthcare providers to deliver a better patient and staff experience, as well as a lower cost of care. As part of our ecosystem approach to enable continuous patient monitoring across multiple care environments, Philips also has a commercial relationship with BioIntelliSense for its medical grade BioSticker and BioButton wearable devices and data services for remote monitoring of populations. of patients at risk.
– Rich Wilmot, Managing Partner, Philips Health Technology Ventures
“Fresenius Medical Care North America (FMCNA) is committed to helping more people living with chronic kidney disease through earlier interventions and has proudly invested in BioIntelliSense as a leading innovation in health sensors and services remotely to speed up home medical surveillance. With the BioSticker and BioButton, our medical staff can continuously monitor patients more efficiently and effectively between treatments with actionable clinical information and facilitate accurate and timely interventions to reduce the cost of care.
– Jeff Burbank, Director of Strategy and Transformation of FMCNA
“BioIntelliSense has implemented a comprehensive and innovative approach to attractively priced, medical grade remote monitoring with strong reimbursement coverage, making it deployable at scale in a way that can revolutionize the industry,” said
– Dawn Owens, CEO of TripleTree Holdings
“Through public and private partnerships, a new era of technological innovation has enabled unprecedented response and preparedness to public health emergencies. The BioIntelliSense BioButton solution is a defining example in combining medical grade wearable devices and assays for the early detection of signs and symptoms associated with an infectious process. This continued ability to monitor vital signs and screen health has proven to be of benefit to patients and frontline healthcare workers, as well as businesses, by enabling a safe return to work, to the workplace. school, travel and large-scale events.
– James Murren, private investor and former CEO of MGM Resorts International.